Peter Barton Hutt Appointed to Concert Pharmaceuticals Board Of Directors

Concert Pharmaceuticals, Inc.

Peter Barton Hutt Appointed to Concert Pharmaceuticals Board Of Directors

December 11, 2006

Lexington, MA –December 11, 2006 – Concert Pharmaceuticals, Inc. announced today the appointment of Peter Barton Hutt as a member of its Board of Directors. Mr. Hutt is a senior counsel in the Washington, DC law firm of Covington and Burling, specializing in food and drug law. Previously, he was Chief Counsel for the Food and Drug Administration.

“Peter is one of the world’s foremost attorneys concerning FDA matters, and an expert in US health policy. We are delighted that he has joined Concert’s Board of Directors,” said Roger Tung, Ph.D., President and CEO of Concert. “Both as a director and as a member of Concert’s Product Advisory Board, his regulatory perspective and knowledge of the biotech and pharmaceutical industries will be invaluable as we advance Concert’s broad product pipeline.”

Peter is a member of the Institute of Medicine of the National Academy of Sciences, and serves on a wide variety of academic and scientific advisory boards and on the Board of Directors of venture capital start-up companies. He recently served on the Panel on Administrative Restructuring of the National Institutes of Health. In addition, he currently teaches food and drug law at Harvard Law School and has also taught at Stanford Law School. He has published numerous papers on food and drug law and on health policy and in 2005 was presented the FDA Distinguished Alumni Award by FDA Commissioner Crawford. Also in 2005, he was given the Lifetime Achievement Award by the Foundation for Biomedical Research, for research advocacy. Peter received his B.A., magna cum laude, from Yale University, his LL.B. from Harvard University, and his LL.M. from New York University.

About Concert Pharmaceuticals

Concert Pharmaceuticals was co-founded in April 2006 by Roger Tung, Richard Aldrich and Christoph Westphal. Dr. Tung had previously served as Vice President of Drug Discovery at Vertex Pharmaceuticals, and is an inventor of Vertex’s two marketed products. By applying insights derived from existing biologically active compounds, Concert aims to create proprietary and improved medicines while dramatically reducing R&D costs and increasing the probabilities of commercial success.


Nancy Stuart
SVP Corporate Strategy and Operations
Concert Pharmaceuticals
+1-781-860-0045 ext. 205